Urothel PD-L1
Urothelial Carcinoma
CommercialActive
Key Facts
About Mindpeak
Mindpeak is a Hamburg-based AI/ML company operating at the intersection of digital pathology and precision medicine. It has developed a suite of CE-marked, deep learning-based software products that automate the analysis of immunohistochemistry (IHC) and H&E-stained tissue samples, primarily for oncology biomarkers like PD-L1, HER2, and Ki-67. The company's value proposition centers on '0-click' integration, offering both standalone and deeply embedded solutions within partner laboratory information systems to improve pathologist efficiency and diagnostic consistency. Mindpeak appears to be in a commercial, revenue-generating stage, serving diagnostic labs, hospitals, and research institutions.
View full company profileTherapeutic Areas
Other Urothelial Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Enfortumab vedotin | astellas | Phase 3 |
| Disitamab Vedotin (RC48) | RemeGen | Approved |
| Erdafitinib | Johnson & Johnson | Phase 3 |
| UGN-501 | UroGen Pharma | Preclinical |